Analysts Set Expectations for Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Zura Bio in a report issued on Wednesday, March 26th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($0.77) for the year. Chardan Capital currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Chardan Capital also issued estimates for Zura Bio’s FY2026 earnings at ($0.78) EPS.

ZURA has been the topic of several other reports. Guggenheim reissued a “buy” rating and set a $15.00 price target on shares of Zura Bio in a report on Wednesday. Oppenheimer reissued an “outperform” rating and issued a $19.00 target price (down from $20.00) on shares of Zura Bio in a research report on Wednesday. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $15.00.

Zura Bio Stock Up 1.5 %

Shares of NASDAQ ZURA opened at $1.36 on Friday. Zura Bio has a 52-week low of $1.07 and a 52-week high of $6.35. The firm’s 50-day moving average price is $1.47 and its 200-day moving average price is $2.75.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds have recently modified their holdings of ZURA. Geode Capital Management LLC boosted its holdings in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after buying an additional 377,545 shares during the period. Barclays PLC lifted its position in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after acquiring an additional 56,757 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock valued at $94,000 after acquiring an additional 10,231 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Zura Bio during the third quarter worth about $71,000. Finally, Braidwell LP bought a new stake in Zura Bio during the 3rd quarter valued at approximately $10,040,000. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.